Global segment ranking · Healthtech › Biotech

The world’s most valuable AI drug discovery startups

AI-first biotechs and drug design platforms that use machine learning to discover and develop new medicines. Ranked worldwide by AI-estimated valuation. The market sets the value; our AI estimates it.

Edition 0 (beta) · Published September 29, 2026 Twice a yearNext edition: January 1, 2027· Claude · multi-AI consensus in a future edition· Published method· Order never changed by a human

Key metrics for this segment: clinical pipeline, pharma partnerships, revenue. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.

Not in this segment. Gene and cell therapy developers, AI for imaging and pathology, in-vitro diagnostics and clinical software each have their own segment. A company appears in one segment only. Method

The segment at a glance

13companies ranked

8companies on the radar

4countries in the ranking

6listed benchmarks

Sources: Endpoints News, Fierce Biotech, BioSpace, STAT, BioXconomy, SiliconANGLE, TechCrunch, BusinessWire, PR Newswire, Contrary Research, Wikipedia, company announcements. Intention counters will be shown above a threshold of amount and number of Backers.

Rankings by region

Filter the ranking and the Radar. Ranks stay worldwide.

Global ranking · AI drug discovery

Top 13 Radar Challengers

First edition: no movements yet.

World · 13 ranked companies

#	Company	Last round · Key metrics	Estimated valuation (AI, order of magnitude)	Confidence	Invest
1	Chai DiscoveryUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series C · USD 400M · Jul 2026Clinical pipeline: n/d · Models deployed with Eli Lilly and Pfizer · Revenue: n/d · 2026	Last known equity round: Series C · USD 400M · Jul 2026 (led by Index Ventures, with Kleiner Perkins, Sequoia Capital, Dimension) Published valuation: USD 3.8bn (Jul 2026) Confidence index: HighMethod	Solid sources	Declare an intent
2	Earendil LabsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Equity financing · USD 787M (several financing rounds) · Mar 2026Clinical pipeline: n/d · Sanofi worldwide licence for bispecifics HXN-1002/HXN-1003 plus broader AI collaboration · Revenue: n/d · 2025	Last known equity round: Equity financing · USD 787M (several financing rounds) · Mar 2026 (Dimension Capital, DST Global, INCE Capital, Sanofi, Biotech Development Fund) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
3	Xaira TherapeuticsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Launch financing · USD 1B+ committed · Apr 2024Clinical pipeline: n/d · Seeking first pharma partners · Revenue: n/d · 2026	Last known equity round: Launch financing · USD 1B+ committed · Apr 2024 (ARCH Venture Partners, Foresite Labs, F-Prime, NEA, Sequoia, Lux, Lightspeed) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
4	EnvedaUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series E · USD 311M · Sep 2026Lead ENV-294 in Phase 1b (atopic dermatitis) · Pharma partnerships: n/d · Revenue: n/d · Sep 2025	Last known equity round: Series E · USD 311M · Sep 2026 (led by Catalio Capital Management, with Iconiq) Published valuation: USD 2bn (Sep 2026) Confidence index: HighMethod	Solid sources	Declare an intent
5	Pathos AIUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series D · USD 365M · May 2025Clinical-stage oncology pipeline, incl. a Novo Nordisk-licensed solid tumour drug · Pharma partnerships: n/d · Revenue: n/d · 2025	Last known equity round: Series D · USD 365M · May 2025 (new and existing investors (incl. NEA, General Atlantic)) Published valuation: USD 1.6bn (May 2025) Confidence index: HighMethod	Solid sources	Declare an intent
6	Formation BioUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series D · USD 372M · Jun 2024Key metrics not disclosed	Last known equity round: Series D · USD 372M · Jun 2024 (led by Andreessen Horowitz and Sanofi) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
7	Iambic TherapeuticsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Equity round · over USD 100M · Nov 2025IAM1363 (HER2) in Phase I/Ib; KIF18A and CDK2/4 programs due in clinic by end-2026 (Sep 2026) · Takeda (up to $1.7B+), AbbVie, Revolution Medicines, Lundbeck (2026) · Revenue: n/d	Last known equity round: Equity round · over USD 100M · Nov 2025 (Sequoia, ARK, Regeneron Ventures, Mubadala, Qatar Investment Authority and others) No confirmed published valuation Confidence index: MediumMethod	Partial sources	Declare an intent
8	insitroUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series C · USD 400M · Mar 2021No clinical trial started (May 2025) · ~$150M non-dilutive pharma partnership funding (cumulative) (Jan 2026) · Revenue: n/d	Last known equity round: Series C · USD 400M · Mar 2021 (led by Canada Pension Plan Investment Board) Published valuation: USD 2.4bn (Mar 2021) Confidence index: MediumMethod	Partial sources	Declare an intent
9	OwkinFrance · EuropeSources: 1 · 2Is this your company? Report an error	Strategic equity · USD 180M · Nov 2021Clinical pipeline: n/d · K Pro licences with AstraZeneca and Sanofi · Revenue: n/d · 2026	Last known equity round: Strategic equity · USD 180M · Nov 2021 (Sanofi) Published valuation: over USD 1B (unicorn) (Nov 2021) Confidence index: LowMethod	Weak sources	Declare an intent
10	Basecamp ResearchUnited Kingdom · EuropeSources: 1Is this your company? Report an error	Series C · USD 140M · Sep 2026Key metrics not disclosed	Last known equity round: Series C · USD 140M · Sep 2026 (led by S32, with Nvidia and Anthology Fund) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
11	Genesis Molecular AIUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Strategic equity · USD 40M · May 2026Clinical pipeline: n/d · Incyte collaboration expanded, with USD 40M equity investment · Revenue: n/d · May 2026	Last known equity round: Strategic equity · USD 40M · May 2026 (Incyte) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
12	CradleNetherlands · EuropeSources: 1 · 2Is this your company? Report an error	Series B · USD 73M · Nov 2024Clinical pipeline: n/d · 21+ customers incl. Novo Nordisk, J&J Innovative Medicine, Grifols · Revenue: n/d · Nov 2024	Last known equity round: Series B · USD 73M · Nov 2024 (led by IVP, with Index Ventures and Kindred Capital) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
13	AqemiaFrance · EuropeSources: 1Is this your company? Report an error	Series A extension · USD 38M · Dec 2024Key metrics not disclosed	Last known equity round: Series A extension · USD 38M · Dec 2024 (led by Cathay Innovation, with Wendel, Bpifrance, Eurazeo, Elaia) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent

Ranking in descending order of AI-estimated valuation, based on public information, following a published method, with no human intervention on the order. Valuation ranges are indicative editorial estimates: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Edition 0: produced by Claude (Anthropic); a consensus of several AI models will apply in a future edition. Eligibility: at least $1M raised including one equity round, non-listed company, main activity in this segment (AI-first drug discovery and molecular design). Country shown is the country of main operations. Request a correction

Get every new edition

New entries, exits and movements, twice a year.

One e-mail per edition. One-click unsubscribe. No data passed on to third parties.

How to read this ranking

Rank

Companies are ranked by AI-estimated valuation, highest first. The market sets the value; our AI estimates it.

Range

An order of magnitude, never a figure.

Hundreds of k$
Millions $
Tens of M$
Hundreds of M$
Unicorn
Decacorn

Confidence

High: recent published valuation or round (under 24 months).
Medium: older data.
Low: single or unconfirmed source.

Full method →

Invest in aI drug discovery, together

Uback aggregates investment intentions from business angels, family offices, corporates and sector specialists worldwide. Every ranked company already has professional investors on its cap table, who have negotiated a shareholders’ agreement: you don’t start from a blank page.

Strength in numbers

Alone, a small ticket opens no doors. Together, Backers carry weight.

Declare an intention

On a company or a sector, with a ticket range. Paid, to show you are serious; transferable as long as it has not been converted.

Critical mass is reached

When the number of Backers and the total of their intentions cross a threshold, the licensed partner contacts the company and presents this demand.

The licensed partner structures

If the company’s expectations and the Backers’ converge, the partner builds a transaction and presents it directly to the Backers concerned.

Closing

Capital raise or sale of existing shares: small tickets are pooled in a common vehicle set up by the licensed partner. Each Backer decides whether to take part.

Uback does not advise, does not negotiate, collects nothing. Each transaction is run by the licensed partner of the company’s country, under the law that governs its shares.

Get notified when intentions open What happens after my declaration? Intention declarations open once the licensed partner signs · price per ticket band · valid 12 months · transferable credit

Challengers

A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.

Sponsored space · no Challenger listed yet

Radar · known eligible companies, not ranked

Sorted by date of last round, with no judgement and no AI call.

MindRank AI · China · Asia-PacificJul 2026 · USD 52M
Drug Farm · China · Asia-PacificJul 2026 · USD 55M
Galux · South Korea · Asia-PacificFeb 2026 · USD 29M
Proxima (formerly VantAI) · United States · North AmericaJan 2026 · USD 80M
Converge Bio · Israel · Middle East & North AfricaJan 2026 · USD 25M
Boltz · United States · North AmericaJan 2026 · USD 28M
Latent Labs · United Kingdom · EuropeFeb 2025 · USD 40M
Bioptimus · France · EuropeJan 2025 · USD 41M

Listed benchmarks

Not ranked: no intention is possible on a listed company.

Insilico Medicine · Hong KongHKEX · 3696
XtalPi · ChinaHKEX · 2228
Recursion Pharmaceuticals · United StatesNASDAQ · RXRX
Generate:Biomedicines · United StatesNASDAQ · GENB
Schrödinger · United StatesNASDAQ · SDGR
Absci · United StatesNASDAQ · ABSI

Sources and method for this segment

Calendar. Global segment rankings are published twice a year. Next edition: January 1, 2027.

Eligibility. At least $1M raised including one equity round, non-listed company, main activity in this segment (AI-first drug discovery and molecular design). A company appears in one segment only.

Sources. Endpoints News, Fierce Biotech, BioSpace, STAT, BioXconomy, SiliconANGLE, TechCrunch, BusinessWire, PR Newswire, Contrary Research, Wikipedia, company announcements.

Method and rules, common to all rankings →